Human donors targeting the post-fusion RSV F protein using human hybridoma technology
Alternative Names:
RSV, Orthopneumovirus
Reactivity Species : Respiratory Syncytial<_Virus Expression Host : HEK-293 Endotoxin Level : 1.0 EU/mg as determined by the LAL method Specificity : RSV-12I1 activity is directed against antigenic site II of the RSV fusion (F) protein. Clone RSV-12I1 did bind to both pre- and post-fusion F protein in an ELISA binding assay, favoring the post-fusion conformation. Competition-binding studies showed that RSV-12I1 targets antigenic site II, which is the target of palivizumab, an antiviral monoclonal antibody licensed as a prophylactic treatment. RSV-12I1 readily competed with RSV-14N4 on post-fusion F, but the competition was less pronounced on pre-fusion F. RSV-12I1 also competed with palivizumab on post-fusion F in a palivizumab competition assay. Saturation alanine scanning mutagenesis identified residues Leu467 and Lys470 as critical for RSV-12I1 binding. Binding was not detected to scaffolded epitopes containing site II.
Clonality:
Monoclonal
Clone Designation:
[RSV-12I1]
Purity:
>=95% monomer by analytical SEC
* VAT and and shipping costs not included. Errors and price changes excepted
